A. Abendroth

Main-Author

• Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance – successful treatment with lenalidomide and dexamethasone

L. Alberio

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies
• Usefulness of global assays to monitor treatment of a patient with Hemophilia A switching from factor to non-factor replacement therapy
• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland
• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

M. C. Alessi

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection
• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

A. Aliotta

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies
• Usefulness of global assays to monitor treatment of a patient with Hemophilia A switching from factor to non-factor replacement therapy
• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

J. Allardet-Servent

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

T. Anderle

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

V. Andreozzi

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

F. Auge

Co-Author

• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

C. Ay

Co-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency
• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

W. Azar

Co-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

C. Bacher

Main-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

M. Bacher

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX

R. Beier

Co-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

D. Bernot

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection
• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

D. Bertaggia Calderara

Main-Author

• Usefulness of global assays to monitor treatment of a patient with Hemophilia A switching from factor to non-factor replacement therapy

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies
• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

C. Bidlingmaier

Main-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

M. Binder

Main-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

N. B. Binder

Co-Author

• Comparing automated FXIII assays

I. Birschmann

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

A. C. Block

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

H. Block

Co-Author

• Examination of the Rac-modulator ArhGAP15 in platelet activation.

H. Bock

Co-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

S. Bockel

Main-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

C. Bode

Co-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

B. Bomke

Co-Author

• Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance – successful treatment with lenalidomide and dexamethasone

S. Bonanad

Main-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

E. Bontekoe

Co-Author

• Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate
• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.
• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

J. C. Bordet

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

R. Bottega

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

C. Bovet

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

P. Bradacova

Main-Author

• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?

Co-Author

• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

P. T. Brinkkoetter

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

N. Buchtele

Main-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip

U. Budde

Co-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

L. Buresch

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

V. Buxhofer-Ausch

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

S. Cabantous

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

M. Canault

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

A. Cappenberg

Co-Author

• Examination of the Rac-modulator ArhGAP15 in platelet activation.

I. Ćelap

Co-Author

• Impact of DOAC Dipstick test and relation to plasma and urine concentrations to exclude the presence of clinically relevant concentrations of DOACs in real-life patient setting – study protocol and case reports

T. Chang

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

K. Chasakova

Main-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib

P. Claar

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX
• Characterization of rFIX fusion proteins enabling subcutaneous administration

D. Crettaz

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies

B. Daravath

Co-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

C. De Ford

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

B. Dharavath

Main-Author

• Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.

R. Dieter

Co-Author

• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder

R. Dieter Jr.

Co-Author

• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder

B. Dixer

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

R. Djedidi - Amrane

Main-Author

• Cancer cell-derived microparticles expressing tissue factor have pivotal role on the procoagulant shift of endothelial cells

H. Domanovits

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study

L. Donner

Co-Author

• The role of platelet mitochondrial function for platelet mediated Aβ40 aggregation

J. Dreier

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

C. Dubois

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

S. Dunoyer-Geindre

Co-Author

• Insight into the role of miR-223-3p in regulating platelet reactivity

W. Eberl

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

H. Eichler

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

I. Elalamy

Co-Author

• International Myeloma Working Group ( IMWG) score accuracy in multiple myeloma patients: need for action.
• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

M. Elvers

Co-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets
• The role of platelet mitochondrial function for platelet mediated Aβ40 aggregation

C. Escuriola-Ettinghausen

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research
• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

C. Falaise

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

M. Faleschini

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

J. Fareed

Co-Author

• Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.
• Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate
• Hepatic Disorders Contribute to Platelet Dysfunction
• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.
• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

A. Farooqui

Co-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

T. Feige

Main-Author

• The role of platelet mitochondrial function for platelet mediated Aβ40 aggregation

M. Fillitz

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

B. Fischer

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

J. Fischer

Co-Author

• Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance – successful treatment with lenalidomide and dexamethasone

R. Fischer

Main-Author

• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

Co-Author

• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication

T. Flasch

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

T. Flieder

Main-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

G. Fontana

Main-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

P. Fontana

Co-Author

• Insight into the role of miR-223-3p in regulating platelet reactivity
• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

M. Fraga

Co-Author

• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

C. Freiburg

Co-Author

• The role of platelet mitochondrial function for platelet mediated Aβ40 aggregation

C. Gachet

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

A. Garcia

Main-Author

• Insight into the role of miR-223-3p in regulating platelet reactivity

L. Garderet

Co-Author

• International Myeloma Working Group ( IMWG) score accuracy in multiple myeloma patients: need for action.

H. Gebhart

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

J. Gebhart

Co-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency

M. George

Co-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

B. Gerber

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

G. Gerotziafas

Co-Author

• Prolonged chemotherapeutic stress is accompanied by an aggressive and singular vascularization process with a high thrombogenic potential in Colorectal Cancer
• Cancer cell-derived microparticles expressing tissue factor have pivotal role on the procoagulant shift of endothelial cells
• International Myeloma Working Group ( IMWG) score accuracy in multiple myeloma patients: need for action.
• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

T. Giangregorio

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

G. Goldmann

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

J. Goldstein

Main-Author

• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder

S. Gottstein

Co-Author

• Monitoring pain and joint health in patients with haemophilia

L. Graf

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

N. Granzow

Main-Author

• Monitoring pain and joint health in patients with haemophilia

L. Gremer

Co-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

H.-J. Groß

Co-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

M. Grube

Co-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

N. Hagedorn

Main-Author

• Noonon syndrome as unlikely cause of increased bruising in a case of suspected battered child syndrome

P. Halfon

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

S. Halimeh

Co-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

C. Hardy

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX
• Characterization of rFIX fusion proteins enabling subcutaneous administration

J. Harenberg

Co-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip
• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Interaction of direct oral anticoagulants and other anticoagulants on DOAC Dipstick test
• Impact of DOAC Dipstick test and relation to plasma and urine concentrations to exclude the presence of clinically relevant concentrations of DOACs in real-life patient setting – study protocol and case reports
• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

C. Hart

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication
• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

H. Haslacher

Co-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency

B. Hechler

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

I. Hegemann

Main-Author

• Evaluation of thrombin generation in patients with sickle cell disease in stable disease and sickle cell crises

S. Heimerl

Co-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

H. Herkner

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

W. Herr

Co-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

H.-J. Hertfelder

Main-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

S. Hetjens

Main-Author

• Interaction of direct oral anticoagulants and other anticoagulants on DOAC Dipstick test

N. Hezard

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

A. Hlusi

Co-Author

• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?
• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

S. Hofer

Co-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency

T. Hoffmann

Co-Author

• Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance – successful treatment with lenalidomide and dexamethasone

K. Holstein

Main-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication

Co-Author

• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

S. Holzhauer

Co-Author

• Real-world experience on the use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional, post-market surveillance study in Germany

D. Hoppenstaedt

Co-Author

• Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.
• Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate
• Hepatic Disorders Contribute to Platelet Dysfunction
• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

M. Höpting

Main-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

B. Ho-Tin-Noé

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

M. Iacobelli

Co-Author

• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

M. Ibrahim-Kosta

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

O. Iqbal

Co-Author

• Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate
• Hepatic Disorders Contribute to Platelet Dysfunction
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.

E. Janus-Bell

Main-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

W. Jeske

Main-Author

• Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.

Co-Author

• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

B. Jilma

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip
• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

S. Kathemann

Co-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

J. Kaufeld

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

B. Kemkes-Matthes

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

K. Kentouch

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

R. Klamroth

Co-Author

• Monitoring pain and joint health in patients with haemophilia
• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

C. Knabbe

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

P. N. Knöbl

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

R. Knöfler

Co-Author

• Laboratory phenotype variability in genetically proven von Willebrand disease type 2B

S. Knoll Machado

Main-Author

• In vitro characterization of K5A and K5R variants of Factor IX

F. Knüttgen

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

R. H. Ko

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

C. Königs

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

A. Kouta

Main-Author

• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

Co-Author

• Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.
• Sulodexide as a Parenteral Anticoagulant. A Substitute for Unfractionated Heparin.

R. Kraemer

Co-Author

• Quantification of Bovine and Porcine Heparin Red Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics.

B. Krammer-Steiner

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication

D. Kranzhöfer

Main-Author

• Type 2B von Willebrand disease – a rare cause of neonatal thrombocytopenia

T. Kraushaar

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX

M. Krohn-Grimberghe

Co-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

M. Krstic

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

I. Krueger

Main-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

P. Kuebler

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

K. Kurnik

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII
• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

T. Lang

Main-Author

• Reversal of DOAC in RVV-test on the ClotPro analyzer

A. K. Larsen

Co-Author

• Prolonged chemotherapeutic stress is accompanied by an aggressive and singular vascularization process with a high thrombogenic potential in Colorectal Cancer

M. Leitner

Main-Author

• Comparing automated FXIII assays

L. M. Lepatan

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

Y. Li

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

T. Lissitchkov

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

C. Liu

Co-Author

• Thrombopoietin levels in sepsis and septic shock - a meta-analysis.
• Examination of the Rac-modulator ArhGAP15 in platelet activation.

M. Loosveld

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

A. Lovrenčić-Huzjan

Co-Author

• Impact of DOAC Dipstick test and relation to plasma and urine concentrations to exclude the presence of clinically relevant concentrations of DOACs in real-life patient setting – study protocol and case reports

J. Machacek

Main-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

M. E. Mancuso

Main-Author

• A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A
• A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

L. Mangels

Co-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

P. Mangin

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

C. Marconi

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

S. Margetić

Main-Author

• Impact of DOAC Dipstick test and relation to plasma and urine concentrations to exclude the presence of clinically relevant concentrations of DOACs in real-life patient setting – study protocol and case reports

A. Margraf

Main-Author

• Thrombopoietin levels in sepsis and septic shock - a meta-analysis.
• Examination of the Rac-modulator ArhGAP15 in platelet activation.

G. Maro

Co-Author

• A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A
• A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain

S. Marten

Main-Author

• Laboratory phenotype variability in genetically proven von Willebrand disease type 2B

A. Martin

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies

A. Matzdorff

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

E. Mbemba

Co-Author

• Cancer cell-derived microparticles expressing tissue factor have pivotal role on the procoagulant shift of endothelial cells

D. Mege

Main-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

J. L. Mege

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

D. Mehic

Main-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency

V. Meißner

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

A. Mendez

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

J. Menne

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

A. Merrelaar

Main-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip

Co-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

O. Meyer

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

W. Miesbach

Co-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

M. Mischnik

Co-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

C. Mischung

Co-Author

• Noonon syndrome as unlikely cause of increased bruising in a case of suspected battered child syndrome

W. Mondorf

Main-Author

• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

D. Moradpour

Co-Author

• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

P. E. Morange

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection
• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

M. C. Morel-Kopp

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

C. Mouriaux

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

B. Müller

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

C. Muret

Main-Author

• Evaluation of different processing methods to label platelets for in vivo studies

S. Naas

Main-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

A. Nagao

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

M. Nagler

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

C. Negrier

Main-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

A. Nemani

Main-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

U. Neudorf

Co-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

F. Nimmerjahn

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

A. Nimtz-Talaska

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication

S. Nolli

Co-Author

• Insight into the role of miR-223-3p in regulating platelet reactivity

M. W. Nolte

Co-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

P. Noris

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

R. Núñez

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

J. Oldenburg

Main-Author

• Real-world experience on the use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional, post-market surveillance study in Germany

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

D. Olive

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

M. Olivieri

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research
• Real-world experience on the use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional, post-market surveillance study in Germany
• A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A
• A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain

I. Pabinger

Main-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

Co-Author

• Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency
• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

L. Panicot-Dubois

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

N. Papa

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

L. Papageorgiou

Main-Author

• International Myeloma Working Group ( IMWG) score accuracy in multiple myeloma patients: need for action.
• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

T. Papajík

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib

L. Paric

Co-Author

• Comparing automated FXIII assays

A. Pavlova

Co-Author

• Type 2B von Willebrand disease – a rare cause of neonatal thrombocytopenia
• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

A. Pecci

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

F. Peiretti

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

S. Pestel

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX
• Characterization of rFIX fusion proteins enabling subcutaneous administration

B. Pezeshkpoor

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

C. Pfrepper

Co-Author

• Real-world experience on the use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional, post-market surveillance study in Germany

C. Pillny

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

M. Pink

Co-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

M. Poggi

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

P. Ponnuswamy

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX

J. L. Poveda

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

J. Prochazkova

Co-Author

• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?
• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

M. Prudent

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies

M. Puceat

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

A. Rath

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

N. Receveur

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

D. Reinhardt

Co-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

J. Reiser

Co-Author

• Cooperation of platelet beta1 and beta3 integrins in the arrest of inflammatory bleeding in mice

J.-L. Reny

Co-Author

• Insight into the role of miR-223-3p in regulating platelet reactivity

M. Reschke

Main-Author

• Causes of Acquired von Willebrands Disease Type II in Pediatric Patients. Cases and literature review.

Co-Author

• Noonon syndrome as unlikely cause of increased bruising in a case of suspected battered child syndrome

H. Richter

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

J. Riedesel

Co-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

M. Rieke

Co-Author

• Reversal of DOAC in RVV-test on the ClotPro analyzer

J. Röder

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX

A. Roesch

Main-Author

• smart medication DocuScan: GSAV-compliant documentation of hemophilia preparations for pharmacies, doctors, treatment centers and patients

C. Rudtke

Co-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

M. J. Rummel

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

G. Ruzicka

Co-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

M. Sabbah

Co-Author

• Cancer cell-derived microparticles expressing tissue factor have pivotal role on the procoagulant shift of endothelial cells

F. Sanabria

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

J. Sangalli-Baruffaldi

Co-Author

• Evaluation of thrombin generation in patients with sickle cell disease in stable disease and sickle cell crises

C. Santoro

Co-Author

• A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A
• A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain

S. Santos

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

T. Sauer

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

P. Saultier

Main-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

N. Saut

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

A. Savoia

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

R. Scharf

Co-Author

• Acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance – successful treatment with lenalidomide and dexamethasone

A. Schmidt

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

D. Schmoldt

Co-Author

• smart medication DocuScan: GSAV-compliant documentation of hemophilia preparations for pharmacies, doctors, treatment centers and patients

H. Schneider

Co-Author

• Type 2B von Willebrand disease – a rare cause of neonatal thrombocytopenia

C. Schoergenhofer

Co-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

K. Schön

Main-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

C. Schörgenhofer

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip

T. Schramm

Co-Author

• Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia

J. Schulte

Co-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

M. Schwameis

Co-Author

• A bedside urine based test strip on identifying anticoagulation with direct oral anticoagulants at a high-volume emergency department – a diagnostic test accuracy study
• Abnormal urine is detected by a specific pad of DOAC Dipstick near patient test strip
• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

W. Seifert

Co-Author

• Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen

M. Seri

Co-Author

• Functional assays to unravell the pathogenetic role of variants found in GFI1B in piastrinopenic patients

K. Severin

Co-Author

• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication
• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication

W. Seyfert-Brandt

Co-Author

• Characterization of rFIX fusion proteins enabling subcutaneous administration

A. Shang

Co-Author

• An analysis of fatalities in persons with congenital hemophilia A (PwcHA) reported in the FDA Adverse Event Reporting System (FAERS) database

F. Siddiqui

Co-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

M. Sigmund

Co-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

A. Skoumalova

Co-Author

• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

L. Slavík

Main-Author

• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib
• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?

P. Sommerer

Co-Author

• A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A
• A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain

A. Spiel

Co-Author

• Clinical usefulness of the novel DOAC Dipstick near patient test strip in emergency settings using semi-automatic DOASENSE Reader

D. Starostka

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib

F. Steffen

Co-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

J. D. Studt

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

S. Šupraha Goreta

Co-Author

• Impact of DOAC Dipstick test and relation to plasma and urine concentrations to exclude the presence of clinically relevant concentrations of DOACs in real-life patient setting – study protocol and case reports

T. Tesanovic

Co-Author

• A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

S. Thouroude

Main-Author

• Prolonged chemotherapeutic stress is accompanied by an aggressive and singular vascularization process with a high thrombogenic potential in Colorectal Cancer

O. Tiebel

Co-Author

• Laboratory phenotype variability in genetically proven von Willebrand disease type 2B

A. Tiede

Co-Author

• Case report: Use of recombinant von Willebrand factor in a patient with acquired von Willebrand syndrome due to specific IgM-antibodies directed against vWF

M. Tollnick

Co-Author

• Reversal of DOAC in RVV-test on the ClotPro analyzer

K. Trautmann

Co-Author

• Laboratory phenotype variability in genetically proven von Willebrand disease type 2B

P. Turcsanyi

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib

M. Türknetz

Co-Author

• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research

J. Úlehlová

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib
• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?
• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

J. Ullrychova

Co-Author

• Non-criteria antiphospholipid antibodies anti-PT/PS, anti-Anexin V: benefit in diagnostics of antiphospholipid syndrome?
• Detection thrombogenicity antiphospolipid antibodies with APC modified TGT

M. Unterberger

Co-Author

• Comparing automated FXIII assays

R. Urbanová

Co-Author

• The occurrence of trombocythopathy in CLL patients treated with Ibrutinib

B. Vandewalle

Co-Author

• A matching‐adjusted indirect comparison in patients with severe haemophilia A: Comparing the efficacy and consumption of rVIII-SingleChain vs two recombinant FVIII

P. Vandreden

Co-Author

• International Myeloma Working Group ( IMWG) score accuracy in multiple myeloma patients: need for action.
• Analysis of adherence to therapy comparing DOAC Dipstick test with plasma concentration of rivaroxaban and apixaban in outpatients with venous thromboembolic disease

P. Van Dreden

Co-Author

• Prolonged chemotherapeutic stress is accompanied by an aggressive and singular vascularization process with a high thrombogenic potential in Colorectal Cancer
• Cancer cell-derived microparticles expressing tissue factor have pivotal role on the procoagulant shift of endothelial cells

D. Van Thiel

Co-Author

• Hepatic Disorders Contribute to Platelet Dysfunction

F. Verrel

Co-Author

• Thrombophilic Phaenotype in a Family with High Frequency of Homozygous Antithrombin Deficiency Typ IIb Budapest 3 and Mild Factor VII Deficiency due to Homozygous Polymorphisms in the Factor 7 Gene and Antithrombotic Treatment

J. Vitte

Co-Author

• Evolution of platelet phenotype during SARS-CoV-2 infection

L. Völker

Main-Author

• Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab

T. Vollmer

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

J. Von Agthoven

Co-Author

• GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

K. von Bargen

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

C. von zur Mühlen

Co-Author

• Differences in venous thromboembolism prophylaxis between gastroenterology and cardiology inpatients.

C. Weiss

Co-Author

• Interaction of direct oral anticoagulants and other anticoagulants on DOAC Dipstick test

S. Wenning

Co-Author

• Real-world experience on the use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional, post-market surveillance study in Germany

C. Wermes

Co-Author

• Annual bleeding rate and factor consumption – comparison between extended and short half-life factor VIII in real life according to electronic documentation smart medication
• Joint bleeds and pain related treatment – comparison of data between 2017 and 2019 according to electronic diary smart-medication
• Development of annual joint bleeds and factor consumption during the last 6 years in 14 haemophilia centers - real life data from electronic documentation smart medication

K. Wieschhaus

Co-Author

• Changes in Vascular Physiology in Patients with ESRD Compared to Patients with ESRD and Concomitant Cardiovascular Disorder

D. Willbold

Co-Author

• Reelin supports Glycoprotein VI and integrin outside-in signaling of platelets

M. W. Nolte

Co-Author

• In vitro characterization of K5A and K5R variants of Factor IX

M. Wolny

Co-Author

• Retrospective analysis of persons after mild COVID-19 in the context of a convalescent plasma donation

W. A. Wuillemin

Co-Author

• Accuracy of the STA®-Liquid anti-Xa assay in clinical practice: results from a large cross-sectional study in Switzerland

Y. Yao

Co-Author

• Sheep Mucosal Heparin as a Substitute for Porcine Mucosal Heparin. A Viable Option to Address the Potential Shortage Crisis.

A. Zarbock

Co-Author

• Thrombopoietin levels in sepsis and septic shock - a meta-analysis.
• Examination of the Rac-modulator ArhGAP15 in platelet activation.

M. G. Zermatten

Main-Author

• Efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis at high thrombotic risk

Co-Author

• Evaluation of different processing methods to label platelets for in vivo studies
• Usefulness of global assays to monitor treatment of a patient with Hemophilia A switching from factor to non-factor replacement therapy

S. Zhou

Co-Author

• Performance evaluation of the BIOPHEN chromogenic test for Factor XIII activity on the Cobas c502 System

B. Zieger

Co-Author

• Type 2B von Willebrand disease – a rare cause of neonatal thrombocytopenia
• Newly diagnosed children and adolescents with haemophilia A and B in Germany – the GEPHARD study of the `Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research